Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

AnaptysBio, Inc. (ANAB)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
28.65+1.34 (+4.91%)
At close: 04:00PM EST
28.65 0.00 (0.00%)
After hours: 04:46PM EST
Advertisement

AnaptysBio, Inc.

10770 Wateridge Circle
Suite 210
San Diego, CA 92121-5801
United States
858 362 6295
https://www.anaptysbio.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees102

Key Executives

NameTitlePayExercisedYear Born
Mr. Daniel R. FagaInterim Pres & CEO and Director3.91kN/A1980
Mr. Eric J. LoumeauCOO & Gen. Counsel639.88kN/A1963
Mr. Hamza Suria M.B.A., M.Sc.Advisory836.53kN/A1976
Dr. Paul F. Lizzul FAAD, M.B.A., M.D., M.P.H., Ph.D.Chief Medical Officer683.17kN/A1975
Mr. Dennis M. MulroyChief Financial OfficerN/AN/A1955
Mr. Benjamin StoneSr. VP of Corp. Devel.N/AN/AN/A
Ms. Beth MuellerSr. VP of HRN/AN/AN/A
Dr. Martin Dahl Ph.D.Sr. VP of ResearchN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Corporate Governance

AnaptysBio, Inc.’s ISS Governance QualityScore as of December 1, 2022 is 8. The pillar scores are Audit: 7; Board: 7; Shareholder Rights: 9; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement